교수진/연구실

  • 교수진
    • 전임교수
  • 연구실
    • 나노약학
    • 물리약학
    • 미생물약품학
    • 병태생리학
    • 산업약제학
    • 생물의약품
    • 생약학
    • 약물약동학
    • 약제학
    • 약품분석
    • 약품제조학
    • 예방약학
    • 생화학
    • 의약화학
    • 임상약학

전임교수

교수정보의 상세 화면
전상민
이름
전상민
학력
박사
전공
약학전공(과)
정보
연구실 :
약학관207호

연구실번호 :
3457

이메일 :
smjeon@ajou.ac.kr

연구관심분야 :
Cancer Metabolism and Signaling Network

홈페이지 :
학력
졸업연도/학교/학위
2011.05 University of Illinois at Chicago 박사
졸업연도/학교/학위
2001.02 서울대학교 석사
졸업연도/학교/학위
1999.02 서울대학교 학사
경력 2012.1~2013,7, Postdoctoral fellow, Research Oncology, Genentech, CA
2001.3~2005.9, Research Scientist, Samsung Biomedical Research Institute, Korea
연구분야 Lab of Integrative Cancer Signaling and Metabolism Network

The international cancer genome project has provided comprehensive repertoire of novel oncogenic mutations at the genomic, epigenomic and transcriptomic levels in many tumor types. In the post-cancer genomics era, cancer research is now focused on defining the functional roles of these novel oncogenes and tumor suppressor genes and exploiting them for targeted cancer therapy. However, given that these oncogenic mutations are numerous and even heterogeneous in many tumors, targeting each individual gene should not be an ideal or promising therapeutic strategy. Thus, understanding the most critical convergent downstream of these diverse oncogenic signaling should be indispensable to warrant successful cancer therapy.
Recently, a growing body of evidence has convincingly shown that diverse oncogenic signaling pathways converge on the regulation of cell metabolism to support energetic demand for deregulated cancer cell growth, proliferation and survival. In this aspect, cancer metabolism research has become emerging hallmark of cancer and one of the hottest fields in cancer research.    

In this view, our lab is interested in studying complex network between oncogenic mutations, signaling and metabolic pathways. We now focus on resolving fundamental and important questions to understand this network by employing bioinformatics, proteomics and metabolomics with in vitro & in vivo genetics tools.

1)Which metabolites/metabolic pathways and oncogenic signaling are regulated by diverse genetic & epigenetic mutations in each tumor type?
2)How these mutations regulate signal transduction and metabolic pathways?
3)How these altered metabolism or metabolic pathways contribute to cancer genesis or maintenance.   
4)Validate identified metabolites or metabolic pathways as potential therapeutic targets as well as diagnostic markers for cancer.

Finally, our long-term goal is to establish diet-metabolism-cancer connection, which will lead us to develop promising strategies for chemoprevention as well as cancer therapy.
논문 및 연구활동
연구활동(주요논문)
  • [논문] A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer (ONCOGENE) - 2017.05
    전상민, 정병진, 이선형, 장수환, 신은애, 김수열, 고현정, 최은지, 유환식
  • [논문] Regulation and Function of AMPK in Physiology and Diseases (EXPERIMENTAL AND MOLECULAR MEDICINE) - 2016.07
    전상민
  • [논문] Spontaneous Hepatocellular Carcinoma after the Combined Deletion of Akt Isoforms (CANCER CELL) - 2016.04
    전상민, Nissim Hay, Wang Qi, Xinyu Chen, Xiao-Ding Peng, Morris J. Birnbaum, Grace Guzman, Wan-Ni Yu
  • [논문] The double-edged sword of AMPK signaling in cancer and its therapeutic implications (ARCHIVES OF PHARMACAL RESEARCH) - 2015.03
    전상민, Nissim Hay
  • [논문] AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress (NATURE) - 2012.05
    전상민, Nissim Hay, Naveedip Chandel
국제학술논문지
  • [논문] A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer (ONCOGENE) - 2017.05
    전상민, 정병진, 이선형, 장수환, 신은애, 김수열, 고현정, 최은지, 유환식
  • [논문] Trans-scirpusin A showed antitumor effects via autophagy activation and apoptosis induction of colorectal cancer cells (ONCOTARGET) - 2017.04
    전상민, 고현정, 진영원, 김진웅, 홍은혜, 이재영, 권보은, 송재형, 허은영, 장선영, 박예정
  • [논문] Cardiac glycosides display selective efficacy for STK11 mutant lung cancer (SCIENTIFIC REPORTS) - 2016.07
    윤석준, 김나영, 임화영, He N, 이철중, 김주현, Mills G, 이혜숙, 김소민, 정유나, 송미, 김우영, 조용연, 전상민, 최진성
  • [논문] Regulation and Function of AMPK in Physiology and Diseases (EXPERIMENTAL AND MOLECULAR MEDICINE) - 2016.07
    전상민
  • [논문] Antiviral Activity of Oroxylin A against Coxsackievirus B3 Alleviates Virus-Induced Acute Pancreatic Damage in Mice (PLoS ONE) - 2016.05
    고현정, 권보은, 송재형, 송혁환, 강주은, 조성찬, 이기종, 심애리, 홍은혜, 김연정, 장선영, 김동은, 전상민, 황삼노
  • [논문] Spontaneous Hepatocellular Carcinoma after the Combined Deletion of Akt Isoforms (CANCER CELL) - 2016.04
    전상민, Nissim Hay, Wang Qi, Xinyu Chen, Xiao-Ding Peng, Morris J. Birnbaum, Grace Guzman, Wan-Ni Yu
  • [논문] The double-edged sword of AMPK signaling in cancer and its therapeutic implications (ARCHIVES OF PHARMACAL RESEARCH) - 2015.03
    전상민, Nissim Hay
  • [논문] The dark face of AMPK as an essential tumor promoter (CELLULAR LOGISTICS) - 2012.10
    전상민, Nissim Hay
  • [논문] AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress (NATURE) - 2012.05
    전상민, Nissim Hay, Naveedip Chandel
  • [논문] The effect of Akt2 deletion on tumor development in Pten+/- mice. (ONCOGENE) - 2012.01
    Nissim Hay, Xu PZ, Peng XD, 전상민, Chen ML
  • [논문] FoxOs Inhibit mTORC1 and Activate Akt by Inducing the Expression of Sestrin3 and Rictor (DEVELOPMENTAL CELL) - 2010.04
    Nissim Hay, Chen CC, Park Y, Nogueira V, Sundararajan D, Tonic I, 전상민, Bhaskar PT
  • [논문] mTORC1 Hyperactivity Inhibits Serum Deprivation-Induced Apoptosis via Increased Hexokinase II and GLUT1 Expression, Sustained Mcl-1 Expression, and Glycogen Synthase Kinase 3β Inhibition (MOLECULAR AND CELLULAR BIOLOGY) - 2009.09
    Nissim Hay, Bhaskar PT, Robey RB, Patra KC, Park Y, 전상민, Nogueira V
  • [논문] Leptin deficiency and beta-cell dysfunction underlie type 2 diabetes in compound Akt knockout mice (MOLECULAR AND CELLULAR BIOLOGY) - 2009.06
    Nissim Hay, Chen WS, Peng XD, Wang Y, Philipson LH, Chen ML, Luo Y, Coleman K, Haschek WM, Bass J, 전상민, Xu PZ
  • [논문] A cytoskeleton-associated protein, TMAP/CKAP2, is involved in the proliferation of human foreskin fibroblasts (BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS) - 2006.09
    박주배, 최봉근, 배창대, 김은희, 성연선, 전상민, 홍경욱
  • [논문] Up-regulation of cytoskeletal-associated protein 2 in primary human gastric adenocarcinomas (JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY) - 2003.11
    박주배, 배창대, 성연선, 안경환, 양한관, 김영일, 박기호, 최종선, 전상민, 서유신
국제학술발표
  • [학술회의] Accelerating precision cancer medicine by integrating cancer genomics with drug repositioning (대한약학회 춘계국제학술대회) - 2017.04
    전상민
  • [학술회의] A clinical drug library screen identifies clobetasol propionate as a potent NRF2 inhibitor and a promising repurposed therapeutic agent for lung cancers with high NRF2 activity (대한약학회 70주년 국제학술대회) - 2016.10
    전상민, 정병진, 김수열, 유환식, 신은애, 최은지, 이선형
  • [학술회의] Understanding metabolic adaptations for cancer therapy (2016 Cancer Metabolism: Light in the Darkness) - 2016.09
    전상민
  • [학술회의] Dual activation of AMPK and NRF2 during metabolic stress defines co-operating antioxidant defense mechanisms in cancer (Keystone Symposia - Frontiers in Cancer Metabolism) - 2016.02
    전상민, Georgia Hatzivassiliou, 최은지
  • [학술회의] Integrative Approaches to Develop Novel Therapeutic Strategies by Exploring the LKB1-AMPK Paradox in Lung Cancer (2015 Bio Korea) - 2015.04
    전상민
  • [학술회의] Therapeutic Implications and Business Development by Regulation of LKB1-AMPK Pathway in Cancer (제 1차 한중 암대사 워크숍) - 2014.12
    전상민
  • [학술회의] Metabolism and Cancer: Old Friends are the Best Friends (2014 Spring International Convention of The Parmaceutical Society of korea) - 2014.04
    전상민
국내학술발표
  • [학술회의] New insights into the mechanisms of metabolic adaptation in cancer ((사)대한약학회 신약개발네트워크분과 창립기념 심포지움) - 2017.04
    전상민
  • [학술회의] AMPK and NRF2 cooperate to promote tumor cell survival during metabolic stress (하이원 신약개발 심포지엄) - 2017.01
    전상민, 최은지, Georgia Hatzivassiliou, 유환식
  • [학술회의] Co-occurring mutations in LKB1 and KEAP1 in lung cancer synergize tumor growth (하이원 신약개발 심포지엄) - 2017.01
    전상민, Georgia Hatzivassiliou, 최은지
  • [학술회의] Clobetasol propionate, a synthetic glucocorticoid, is a novel GSK3-dependent NRF2 inhibitor displaying promising therapeutic efficacy in KEAP1-mutant lung cancers (하이원 신약개발 심포지엄) - 2017.01
    전상민, 김수열, 이선형, 최은지, 정병진
  • [학술회의] Exploiting Metabolic Adaptations for Cancer Therapy (한국유방암학회 중개연구회 심포지엄) - 2016.11
    전상민
  • [학술회의] NRF2 조절을 통한 폐암 치료 신약개발 (신약개발분과회 추계 워크숍) - 2016.10
    전상민
  • [학술회의] Dissecting the Role of AMPK in Cancer (2016 대한신경종양학회 추계학술대회) - 2016.09
    전상민
  • [학술회의] The LKB1-AMPK and KEAP1-NRF2 pathways synergize antioxidant defense during metabolic stress in cancer (2016 cMIG 춘계 워크숍) - 2016.03
    전상민
  • [학술회의] A clinical drug library screen identifies glucocorticoids as novel NRF2 inhibitors and promising repurposed therapeutics for lung cancers with high NRF2 activity. (하이원신약개발심포지아) - 2016.01
    전상민, 최은지, 정병진
  • [학술회의] High frequency of co-occurring mutations in LKB1 and KEAP1 in lung cancer confers combinatorial oncogenic driver pathway allowing concurrent activation of both mTORC1-mediated growth and NRF2-mediated antioxidant defense (하이원신약개발심포지아) - 2016.01
    전상민, Georgia Hatzivassiliou, 최은지
  • [학술회의] Dual activation of AMPK and NRF2 during metabolic stress is a critical fail-safe mechanism for metabolic adaptation in cancer (제5차 암대사 워크숍) - 2015.11
    전상민
  • [학술회의] Novel therapeutic opportunities behind the LKB1-AMPK paradox in lung cancer (The 2nd KSBMB DDC JEJU WORKSHOP) - 2015.07
    전상민
  • [학술회의] Business development by regulation of metabolic pathway in cancer and challenges for clinical application (2015년 한국임상암학회 제 13차 정기 심포지움 및 총회) - 2015.05
    전상민
  • [학술회의] Understanding the LKB1-AMPK pathway in cancer for novel therapeutic interventions (2015년 생명 약학 연구회 동계 심포지엄) - 2015.02
    전상민
  • [학술회의] Developing novel anti-cancer strategies integrating cancer genomics, signaling and metabolism network (2014 Lee Gil Ya Cancer and Diabetes Institute Symposium) - 2014.11
    전상민
  • [학술회의] Exploring the LKB1-AMPK paradox and Its Implications for Cancer Therapy (제 38회 세포생물학회 하계 학술대회) - 2014.07
    전상민
  • [학술회의] Exploring the LKB1 Paradox in Cancer: A Tumor Suppressor with a Key Role in Tumor Stress Adaptation and Its Therapeutic Implications (동아 제 1차 항암 미니 심포지엄) - 2014.04
    전상민
  • [학술회의] Exploring the LKB1 paradox: a tumor suppressor with a key role in tumor stress adaptation (제5회 생화학분자생물학회 동계학술대회) - 2014.01
    전상민
  • [학술회의] Exploring the LKB1-AMPK paradox: A tumor suppressor pathway with a key role in tumor stress adaptation (제1회 아주대학교 의약학 공동 심포지움) - 2013.09
    전상민, Anneleen Daemen, Leisa Johnson, Georgia Hatzivassiliou, David Stokoe
저서 및 번역
  • [저서] 임상독성학 - 2015.03
    전상민
특허 및 기타
  • [특허] 글루코코르티코이드계 화합물을 포함하는 폐암 치료용 약학 조성물 (출원) (PCT/KR2016/012534) - 2016.11
    전상민
  • [특허] 글루코코르티코이드계 화합물을 포함하는 비소세포성 폐암 치료용 약학 조성물 (출원) (10-2016-0135006) - 2016.10
    전상민
  • [특허] 글루코코르티코이드계 화합물을 포함하는 비소세포성 폐암 치료용 약학 조성물 (출원) (10-2015-0153296) - 2015.11
    전상민
수업계획서
갤러리
목록 이미지 등록

빠른 이동 메뉴

quick
  • potal
  • 중앙도서관
  • E클래스
  • 학사정보
  • 장학정보
  • 증명서발급
  • 취업정보
  • 헬프데스크
글자화면확대화면축소top
아주대학교
  • Ajou University, 206 Worldcup-ro, Yeongtong-gu, Suwon, Gyeonggi-do, 16499, KOREA  Tel. +82-31-219-3431
  • COPTRIGHT(C)2016 College of Pharmacy. All Right Reserved.